Treatment Paradigms for Advanced Stage Non-small Cell Lung Cancer in the Era of Multiple Lines of Therapy
Open Access
- 1 February 2009
- journal article
- review article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 4 (2), 243-250
- https://doi.org/10.1097/jto.0b013e31819516a6
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Duration of First-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Less Is More in the Era of Effective Subsequent TherapiesJournal of Clinical Oncology, 2007
- : P2-235: Optimal duration of chemotherapy in non-small-cell lung cancer: multicenter, randomized, prospective clinical trial comparing 4 vs 6 cycles of carboplatin and gemcitabineJournal of Thoracic Oncology, 2007
- Phase II Trial of Cetuximab in Patients With Previously Treated Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancerBritish Journal of Cancer, 2006
- Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results DatabaseJournal of Clinical Oncology, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2005
- Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancerLung Cancer, 2005
- Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective studyCancer, 1989